---
title: "Speciality Medicines Ltd (544738) — Share Price, Financials & Analysis"
symbol: "544738"
company: "Speciality Medicines Ltd"
canonical: "https://tapetide.com/stocks/544738"
bse_code: "544738"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:17:04.544Z"
---

# Speciality Medicines Ltd (544738)

Canonical page: https://tapetide.com/stocks/544738

## Company

- **BSE Code:** 544738
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** specialitymedicine.com

## About

Incorporated in 2021, Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceuticals.[1]

## Latest Price

## Key Insights

### Strengths

- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 27.5%

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Tax rate seems low

## Growth Rates

| Metric | 1Y | 3Y |
| --- | --- | --- |
| net income growth | 81% | 98% |
| revenue growth | 29% | 48% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2025 | Mar 2026 |
| --- | --- | --- |
| Sales | 31 | 45 |
| Expenses | 26 | 36 |
| Operating Profit | 4 | 8 |
| OPM % | 14 | 19 |
| Other Income | 0 | 1 |
| Interest | 0 | 1 |
| Depreciation | 0 | 0 |
| Profit before tax | 4 | 8 |
| Tax % | 36 | -1 |
| Net Profit | 3 | 8 |
| EPS in Rs | 4.16 | 9.31 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 40 | 23 | 28 | 58 | 75 |
| Expenses | 38 | 20 | 22 | 49 | 62 |
| Operating Profit | 2 | 4 | 5 | 9 | 14 |
| OPM % | 6 | 15 | 19 | 16 | 18 |
| Other Income | 0 | 0 | 0 | 0 | 1 |
| Interest | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 2 | 3 | 5 | 9 | 13 |
| Tax % | 31 | 43 | 36 | 17 | 0 |
| Net Profit | 1 | 2 | 3 | 7 | 13 |
| EPS in Rs | 70.48 | 4.42 | 5.73 | 11.19 | 14.83 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Equity Capital | 0.21 | 4 | 5 | 6 | 9 |
| Reserves | 2 | 2 | 10 | 24 | 62 |
| Borrowings | 1 | 4 | 3 | 5 | 7 |
| Other Liabilities | 3 | 4 | 5 | 4 | 17 |
| Total Liabilities | 6 | 13 | 23 | 40 | 95 |
| Fixed Assets | 2 | 2 | 1 | 2 | 2 |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 4 | 11 | 21 | 38 | 93 |
| Total Assets | 6 | 13 | 23 | 40 | 95 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1 | -4 | -5 | -6 | -1 |
| Cash from Investing Activity | -2 | 0 | 0 | -1 | -3 |
| Cash from Financing Activity | 2 | 4 | 5 | 8 | 28 |
| Net Cash Flow | 0 | 0 | 0 | 1 | 24 |
| Free Cash Flow | -1 | -4 | -5 | -7 | -1 |
| CFO/OP | 36 | -101 | -66 | -54 | -9 |

### Ratios

| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Debtor Days | 23 | 87 | 142 | 60 | 128 |
| Inventory Days | 5 | 103 | 161 | 150 | 191 |
| Days Payable | 12 | 40 | 48 | 8 | 80 |
| Cash Conversion Cycle | 16 | 149 | 255 | 202 | 239 |
| Working Capital Days | -3 | 76 | 185 | 181 | 221 |
| ROCE % | — | 52 | 38 | 34 | 25 |

## Shareholding Pattern

### annual

| Category | Mar 2026 |
| --- | --- |
| Promoters | 43.43% |
| FIIs | 0.24% |
| Public | 56.34% |
| No. of Shareholders | 757 |

### Quarterly

| Category | Mar 2026 |
| --- | --- |
| Promoters | 43.43% |
| FIIs | 0.24% |
| Public | 56.34% |
| No. of Shareholders | 757 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 7 / 6 / 6

### Moving Averages — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 153.05 | Buy |
| EMA (10) | 156.04 | Buy |
| SMA (20) | 155.54 | Buy |
| EMA (20) | 157.46 | Buy |
| SMA (50) | 169.89 | Sell |
| EMA (50) | 171.5 | Sell |
| SMA (100) | 210.07 | Sell |
| EMA (100) | 199.67 | Sell |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 56.55 | Neutral |
| MACD (12,26,9) | -3.77 | Buy |
| Stochastic (14,3,3) | 81.92 | Sell |
| ADX (14) | 25.19 | Buy |
| Williams %R (14) | -25.47 | Neutral |
| ATR (14) | 6.93 | High Volatility |
| ROC (12) | 7.17 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 56.75 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 6 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no physical share certificates received for dematerialization. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no physical share certificates received for dematerialization.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f6710af1-f96b-4edb-a193-5f3238e1838e.pdf) |
| 5 Sep - We hereby submit Newspaper publication of Notice of 5th Annual general meeting of the company. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Sep - We hereby submit Newspaper publication of Notice of 5th Annual general meeting of the company.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dbc88836-e606-4063-b368-398fd6a02dfd.pdf) |
| 4 Aug - Speciality Medicines appointed Capital Bridge Advisors as investor and public relations agency on August 4, 2026. | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations 2015 Regarding Appointment Of Investor And Public Relations Agency Of The Company 4 Aug - Speciality Medicines appointed Capital Bridge Advisors as investor and public relations agency on August 4, 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a21e10c4-7f42-4915-ab96-fdc0b65f0150.pdf) |
| 3 Sep - Board approved FY26 report, called AGM on 28 Sep 2026, and appointed voting agency and scrutinizer. | [Board Meeting Outcome for Outcome Of Board Meeting Held On September 03, 2026 3 Sep - Board approved FY26 report, called AGM on 28 Sep 2026, and appointed voting agency and scrutinizer.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c8df00c-0ae0-4b94-87ba-60c3ee81a1ed.pdf) |
| 28 May - Board approved FY26 audited standalone results; profit rose to INR 1,303.29 lakh; IPO proceeds utilized INR 509.15 lakh. | [Board Meeting Outcome for Outcome Of Board Meeting Held On Today I.E On May 28 2026 28 May - Board approved FY26 audited standalone results; profit rose to INR 1,303.29 lakh; IPO proceeds utilized INR 509.15 lakh.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=16e06da0-ed3b-4c63-b4f7-b0c9ce0c1905.pdf) |
| 28 May - Board approved FY26 audited standalone results, unmodified audit opinion, and IPO proceeds utilization on May 28, 2026. | [Results - Financial Results For The Half Year And Year Ended March 31 2026 28 May - Board approved FY26 audited standalone results, unmodified audit opinion, and IPO proceeds utilization on May 28, 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1bf6ccc1-b7f5-4ea8-9007-0c6a95971fa1.pdf) |
| 21 May - Board meets May 28, 2026 to approve FY26 audited standalone results; trading window closed from April 1, 2026. | [Board Meeting Intimation for Meeting Of Board Of Speciality Medicines Limited To Be Held On May 28 2026 21 May - Board meets May 28, 2026 to approve FY26 audited standalone results; trading window closed from April 1, 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=55d20cb1-4289-4702-bbc7-81e35045476c.pdf) |
| 12 Aug - Speciality Medicines received Ethiopia approval for Olanzapine 5 mg and Diazepam 5 mg; 12 products now registered. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 12 Aug - Speciality Medicines received Ethiopia approval for Olanzapine 5 mg and Diazepam 5 mg; 12 products now registered.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77f29b7d-7da6-464e-ab1a-f9487e6bc9d8.pdf) |
| 12 Aug - Received Ethiopia approval for Olanzapine 5 mg and Diazepam 5 mg; portfolio rises to 12 formulations. | [Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 Regarding Approval For Two New Products In Ethiopia 12 Aug - Received Ethiopia approval for Olanzapine 5 mg and Diazepam 5 mg; portfolio rises to 12 formulations.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2fb8f869-81a0-4526-9dd9-fb22ecf0e9cd.pdf) |
| — | [Notice Of 5Th Annual General Meeting 3 Sep](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0c7fd650-53c0-48f2-add6-e0fdc2b0a555.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:17:04.544Z.